Cardiology

A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.

The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.

The investigative therapy for treatment-resistant hypertension resulted in a substantial reduction in ambulatory 24-hour average systolic blood pressure versus placebo.

Read about groundbreaking FDA decisions, exciting new heart failure research, and more.

Recent research refutes the conception that most, if not all, coronary heart disease occurs without typical CVD risk factors.

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Amgen announced that evolocumab reduced the risk of MACEs such as heart attack and stroke in patients without any prior history of these events.

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

Neuen is joined by Richard Pratley, MD, and Muthiah Vaduganathan, MD, MPH, to discuss the evolving landscape of CKM trial design.

New research highlights the benefits of PAP therapy for sleep apnea, showing improvements in blood pressure and cardiometabolic health.

The investigative therapy from Windtree Therapeutics also maintained a favorable safety and tolerability profile versus placebo.

Explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.

Recent analyses detail the ongoing risk of hyperkalemia in heart failure patients, highlighting the importance of optimal medication dosing.

An analysis of data from the HELIOS-B trial indicated an overall reduction in GI events among the vutrisiran cohort compared to those receiving placebo.

Aficamten shows superior exercise capacity improvements over metoprolol for patients with oHCM.

100% of included participants were successfully defibrillated and exhibited 6-month improvements or stability in the majority of patients.

New 96-week data reveals aficamten's significant benefits for patients with nonobstructive hypertrophic cardiomyopathy.

Acoramidis significantly lowers cardiovascular event risk in ATTR-CM, emphasizing the need for early diagnosis & treatment.

Guideline-directed medical therapy and SGLT2i use has been associated with reduced total health care costs and a lower risk of hospitalization and death.

If this connection is proven, the gut microbiome may present an entirely new pathway for treatment and prevention of heart failure.

Patients taking multiple drugs simultaneously receive the same protective effect from finerenone, regardless of their degree of polypharmacy.

New research links marijuana use to higher readmission and mortality rates in heart failure patients.